Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

R. Chiari · SciRah

Researcher profile · Semantic Scholar

R. Chiari

Share profile

R. Chiari — researcher profile on SciRah

h-index: 49
Works: 278
Citations: 11K

Most-cited papers

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
H. Borghaei, S. Gettinger, E. Vokes, L. Chow +26 more
2021Journal of Clinical Oncology512 citations Open access
Semantic Scholar
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.
A. Shaw, B. Solomon, B. Besse, T. Bauer +15 more
2019Journal of Clinical Oncology346 citations Open access
Semantic Scholar
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
A. Shaw, B. Solomon, R. Chiari, Gregory Riely +12 more
2019The Lancet Oncology304 citations
Semantic Scholar
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
A. Cortellini, M. Tucci, V. Adamo, L. S. Stucci +36 more
2020Journal for ImmunoTherapy of Cancer239 citations Open access
Semantic Scholar
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
A. Cortellini, R. Chiari, B. Ricciuti, G. Metro +31 more
2019Clinical Lung Cancer167 citations
Semantic Scholar
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study.
A. Cortellini, S. Buti, D. Santini, F. Perrone +41 more
2019The Oncologist167 citations Open access
Semantic Scholar
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
A. Cortellini, M. di Maio, O. Nigro, A. Leonetti +57 more
2021Journal for ImmunoTherapy of Cancer151 citations Open access
Semantic Scholar
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.
A. Cortellini, M. Bersanelli, D. Santini, S. Buti +34 more
2020European Journal of Cancer112 citations
Semantic Scholar
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
S. Buti, M. Bersanelli, F. Perrone, M. Tiseo +43 more
2020European Journal of Cancer103 citations Open access
Semantic Scholar
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
A. Cortellini, M. Tiseo, G. Banna, F. Cappuzzo +66 more
2020Cancer Immunology and Immunotherapy94 citations Open access
Semantic Scholar
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation
A. Cortellini, B. Ricciuti, M. Tiseo, E. Bria +46 more
2020Journal for ImmunoTherapy of Cancer92 citations Open access
Semantic Scholar
ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
R. Chiari, B. Ricciuti, L. Landi, A. Morelli +11 more
2020Clinical Lung Cancer87 citations
Semantic Scholar
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
M. Santoni, S. Buti, Z. Myint, M. Maruzzo +62 more
2023European Urology Oncology86 citations Open access
Semantic Scholar
Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort
A. Naqash, B. Ricciuti, D. Owen, V. Florou +14 more
2020Cancer Immunology and Immunotherapy80 citations Open access
Semantic Scholar
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes.
A. Cortellini, A. Friedlaender, G. Banna, G. Porzio +67 more
2020Clinical Lung Cancer79 citations Open access
Semantic Scholar
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
M. Canale, E. Petracci, A. Delmonte, G. Bronte +13 more
2020Journal of Clinical Medicine71 citations Open access
Semantic Scholar
Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer.
A. Cortellini, A. D'Alessio, S. Cleary, S. Buti +54 more
2023Clinical Cancer Research70 citations Open access
Semantic Scholar
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study.
O. Nigro, G. Pinotti, F. de Galitiis, F. Di Pietro +47 more
2020medRxiv65 citations Open access
Semantic Scholar
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
M. Lorenzi, A. Ferro, F. Cecere, D. Scattolin +18 more
2021The Oncologist61 citations Open access
Semantic Scholar
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer
G. Banna, A. Cortellini, D. Cortinovis, M. Tiseo +42 more
2021ESMO Open61 citations Open access
Semantic Scholar
Texture Analysis on [18F]FDG PET/CT in Non-Small-Cell Lung Cancer: Correlations Between PET Features, CT Features, and Histological Types
F. Bianconi, I. Palumbo, M. Fravolini, R. Chiari +3 more
2019Molecular Imaging and Biology61 citations
Semantic Scholar
Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario
L. Cantini, G. Mentrasti, G. L. Russo, D. Signorelli +58 more
2022ESMO Open60 citations Open access
Semantic Scholar
Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer
M. Mandarano, E. Orecchini, G. Bellezza, J. Vannucci +8 more
2021International Journal of Molecular Sciences56 citations Open access
Semantic Scholar
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
A. Cortellini, A. De Giglio, K. Cannita, D. Cortinovis +47 more
2021Thoracic Cancer48 citations Open access
Semantic Scholar
Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.
B. Ricciuti, C. Genova, M. Bassanelli, A. De Giglio +7 more
2019Clinical Lung Cancer48 citations
Semantic Scholar
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab
E. Lenci, L. Cantini, Federica Pecci, V. Cognigni +16 more
2021Journal of Clinical Medicine45 citations Open access
Semantic Scholar
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
M. Santoni, F. Massari, Z. Myint, R. Iacovelli +52 more
2023Targeted oncology44 citations Open access
Semantic Scholar
The Tumor-Agnostic Treatment For Patients with Solid Tumors: a Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBIOC-SIF Italian Scientific Societies.
A. Russo, L. Incorvaia, U. Malapelle, M. Del Re +17 more
2021Critical reviews in oncology/hematology42 citations Open access
Semantic Scholar
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool
M. Mandarano, G. Bellezza, M. L. Belladonna, J. Vannucci +14 more
2020Frontiers in Immunology39 citations Open access
Semantic Scholar
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies.
A. Russo, L. Incorvaia, E. Capoluongo, P. Tagliaferri +24 more
2021Critical reviews in oncology/hematology38 citations
Semantic Scholar
ASCEND-7: Efficacy and Safety of Ceritinib Treatment in Patients With ALK-Positive Non-Small Cell Lung Cancer Metastatic to the Brain and/or Leptomeninges.
Laura Q. M. Chow, F. Barlesi, E. Bertino, M. J. van den Bent +15 more
2022Clinical Cancer Research34 citations Open access
Semantic Scholar
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases
D. Cortinovis, R. Chiari, A. Catino, F. Grossi +18 more
2019Anticancer Research34 citations Open access
Semantic Scholar
Antibody-drug conjugates for lung cancer in the era of personalized oncology.
B. Ricciuti, G. Lamberti, Elisa Andrini, C. Genova +5 more
2019Seminars in Cancer Biology34 citations
Semantic Scholar
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
M. Santoni, F. Massari, Z. Myint, R. Iacovelli +52 more
2023Clinical Genitourinary Cancer31 citations Open access
Semantic Scholar
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
A. Cortellini, K. Cannita, M. Tiseo, D. Cortinovis +48 more
2021European Journal of Cancer31 citations Open access
Semantic Scholar
Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.
S. Buti, M. Bersanelli, F. Perrone, S. Bracarda +57 more
2021European Journal of Cancer31 citations Open access
Semantic Scholar
Dexamethasone‐Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High‐Dose Cisplatin: A Randomized Noninferiority Study
L. Celio, D. Cortinovis, A. Cogoni, L. Cavanna +17 more
2021The Oncologist29 citations Open access
Semantic Scholar
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
O. Fiala, S. Buti, Hideki Takeshita, Yohei Okada +88 more
2023Cancer Immunology and Immunotherapy27 citations Open access
Semantic Scholar
Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study
G. Mentrasti, L. Cantini, C. Zichi, N. D'Ostilio +19 more
2022The Oncologist27 citations Open access
Semantic Scholar
Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study
G. Mentrasti, L. Cantini, P. Vici, N. D'Ostilio +16 more
2022Breast25 citations Open access
Semantic Scholar
High PD-L1/IDO-2 and PD-L2/IDO-1 Co-Expression Levels Are Associated with Worse Overall Survival in Resected Non-Small Cell Lung Cancer Patients
V. Ludovini, F. Bianconi, A. Siggillino, J. Vannucci +13 more
2021Genes25 citations Open access
Semantic Scholar
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
A. Cortellini, A. Leonetti, A. Catino, P. Pizzutillo +33 more
2019Clinical and Translational Oncology25 citations Open access
Semantic Scholar
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation
M. Russano, A. Cortellini, R. Giusti, A. Russo +46 more
2021Cancer Immunology and Immunotherapy21 citations Open access
Semantic Scholar
Incidence and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with metastatic castration-resistant prostate cancer
O. Caffo, D. Gasparro, G. Di Lorenzo, A. D. Volta +21 more
2020European Journal of Cancer20 citations Open access
Semantic Scholar
Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)
A. Merlotti, A. Bruni, P. Borghetti, S. Ramella +9 more
2021La radiologia medica19 citations Open access
Semantic Scholar
Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab
C. Genova, Silvia Marconi, G. Chiorino, F. Guana +24 more
2024Clinical and Experimental Medicine (Testo stampato)18 citations Open access
Semantic Scholar
Social distress among medical oncologists and other healthcare professionals during the first wave of COVID-19 pandemic in Italy
R. Berardi, M. Torniai, M. S. Cona, F. Cecere +8 more
2021ESMO Open18 citations Open access
Semantic Scholar
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study
J. Yang, K. Reckamp, Young-chul Kim, S. Novello +15 more
2020JTO Clinical and Research Reports18 citations Open access
Semantic Scholar
Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC
M. Lind, S. Gettinger, H. Borghaei, J. Brahmer +27 more
202018 citations
Semantic Scholar
Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy
G. Banna, M. Tiseo, D. Cortinovis, F. Facchinetti +30 more
2021Thoracic Cancer17 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

A. Cortellini×19
Invite
A. Cortellini — researcher profile on SciRah
R. Giusti×19
Invite
R. Giusti — researcher profile on SciRah
C. Ficorella×19
Invite
C. Ficorella — researcher profile on SciRah
R. Berardi×19
Invite
R. Berardi — researcher profile on SciRah

×18

Invite

M. Filetti — researcher profile on SciRah

Invite

G. Porzio — researcher profile on SciRah

M. De Tursi×16

Invite

M. De Tursi — researcher profile on SciRah

F. Rastelli×15

Invite

F. Rastelli — researcher profile on SciRah

Invite

F. Zoratto — researcher profile on SciRah

Invite

S. Buti — researcher profile on SciRah

Invite

D. Santini — researcher profile on SciRah

Invite

M. Russano — researcher profile on SciRah